RFK Jr.'s peptide policy could boost Hims & Hers as its GLP-1 business evolves
Hims may have a chance to grow peptides business as a potential revenue driver, with FDA review in 2026 shaping the opportunity.
RFK Jr.'s peptide policy could boost Hims & Hers as its GLP-1 business evolves basliginda one cikan gelisme: Hims may have a chance to grow peptides business as a potential revenue driver, with FDA review in 2026 shaping the opportunity.
Fonvera editor notu: Haberin piyasa etkisini izlemek icin ilgili varlik sayfalari ve ekonomik takvim akisi birlikte okunmalidir.